Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best Russell 2000 stocks to buy now. On August 18, Truist Securities ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

HIMS eyes long-term growth with new hormonal health offerings, international expansion and high GLP-1 retention.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors ...

THE healthcare outsourcing market is expanding rapidly worldwide, and the Philippines, with over 200,000 remote professionals ...

Copycat versions of popular drugs like Ozempic and Mounjaro have continued to proliferate in a postshortage era, with some ...

NVIDIA Corporation, Novo Nordisk A/S, Shift4 Payments Inc, Hims Hers Health Inc. Read 's Market Analysis on Investing.com ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...

Discover LifeMD's Q2 performance with slowed revenue growth, revised 2025 guidance, and concerns over margins.

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

An international clinical trail showed the risk of kidneys deteriorating or failing was lower in patients taking Ozempic, as ...

After shares of Novo Nordisk (NVO) fell throughout the last year, the more recent drop may be its last. The company, along with its rival Eli Lilly (LLY), will offer its obesity drug for $499 per ...